A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma.
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Daporinad (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors TopoTarget; TopoTarget Switzerland
- 31 Aug 2018 Biomarkers information updated
- 08 Nov 2012 Actual end date Mar 2009 added as reported by ClinicalTrials.gov.
- 12 Mar 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.